Among the drugs potentially effective against p-PPGLs are Hif2α inhibitors, which to date have been tested against ccRCC [44], and therapeutics targeting DNA methylation such as DNA methyltransferase inhibitors or histone deacetylase inhibitors. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.